J&J signs on Xencor for a $100M licensing deal targeting CD20, looking to press its advantage in bispecifics
With a recent approval for lung cancer bispecific amivantamab, J&J is looking to build a franchise in that space with a growing crop of drugs in the pipeline. The drug giant has now tapped a familiar partner to drive that work ahead, and the pair is going after a well-known target.
J&J’s Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global licensing rights to Xencor’s CD20/CD3 bispecific antibody plamotamab currently in Phase I testing against B cell malignancies, the companies said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.